Navigation Links
Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
Date:7/28/2014

ic fibrosis. We intend to begin a Phase 3 pivotal trial in the United States and Europe in 2015.About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or 510.856.5598. ANTHERA PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except share and per share data)(unaudited)Three months ended June 30,Six months endedJune 30,2014201320142013Operatin
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
2. Anthera Announces First Quarter 2012 Financial Report and Conference Call
3. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
5. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
6. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
10. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Christine Mummery, one of the worlds leading heart stem cell ... Dame Anne McLaren in the keynote lecture of the inaugural ... McLaren was an early pioneer of the study of embryonic ... of IVF treatments and stem cell techniques. , Prof Mummery ...
... natural fatty acids that is sometimes used as a weight-loss ... substances to prevent health problems that can follow rapid weight ... a compound naturally found in some meat and dairy products, ... a recent study in mice found that the hormone leptin ...
... to Complement Renowned Laboratory Information System, ... Inc. (OTC Bulletin Board: GLOB), an international,e-Health, ... its,Wyndgate Technologies(R) (Wyndgate) division has formed a ... CERN ), a,leading provider of healthcare ...
... MIAMI, April 9, 2008 Eurosport Active World, ... World, Corp. and,Eagle International Holdings Group, Inc. have ... Corp., whose common stock,trades on the "Pink Sheets" ... Inc. have merged. Subsequent to a 1000:1 reverse ...
... could be missed, harming long-term survival, study suggests , , ... analysis of breast cancer patient survival suggests it might ... node biopsies. , A team of New York City ... to be free of cancerous cells in their sentinel ...
... April 9, 2008 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited ... marketer of medical devices in China with a ... Cheng, Mindray,s,executive vice president of strategic development and ... the JPMorgan 4th Annual China,Conference to be held ...
Cached Medicine News:Health News:Heart stem cell scientist to honor pioneering woman scientist in keynote speech 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 3Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 2Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 4Health News:Mindray to Attend the JPMorgan 4th Annual China Conference 2
... The Calypte AwareTM HIV-1/2 OMT test ... in vitro immunoassay for the,detection of antibodies ... and Type 2 (HIV-2) in human oral,mucosal ... as a point-of-care aid in the clinical ...
... the first HbA1c control available with intact ... HbA1c procedure including the lysing of the ... ready-to-use liquid control with an open-vial stability ... of six months when refrigerated. A1c-Cellular is ...
...
...
Medicine Products: